Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 213

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 213
---
 $ | 120,000 |     | $ | 100,000 |
| Directors’ remuneration         
 to Ms. Fong Hei Yue, Tina       |     |              | 125,000 |   |     |   | 120,000 |     |   | 100,000 |
| Waiver of related party balance 
 of Mr. Siu Wing Fung, Alfred    |     |              | (88,151 | ) |     |   |       — |     |   |       — |

NOTE 16 — LOAN TO A SPAC I On June 12, 2023, NewGenIvf Limited (the “Company”) and A SPAC I Acquisition Corp (“A SPAC I”) entered into a First Amendment to Merger Agreement, pursuant to which the Company agreed to provide non-interest bearing loans in an aggregate principal amount of up to $ 560,000(the “Loan”) to A SPAC I to fund amounts required to further extend the period of time available for A SPAC I to consummate a business combination, and for working capital and payment of professional, administrative and operational expenses, and other purposes as mutually agreed by A SPAC I and the Company. The Loan will only become repayable upon the closing of the Acquisition Merger. As of December 31, 2023, $ 140,000was outstanding under the loan. The Company completed the business combination with A SPAC I Acquisition Corp on April 3, 2024. After the combination, the balance of loan to A SPAC I was eliminated in the subsequent period. NOTE 17 — IMPACT OFCOVID-19 The COVID-19 has negatively impacted the global economy, disrupted consumer spending and global supply chains, and created significant volatility and disruption of financial markets. The Company experienced some resulting disruptions to the Company’s business operations, and the Company expected the COVID-19 pandemic could have a material adverse impact on the Company’s business and financial performance. Due to the ongoing recession caused by the COVID-19, the Company’s business is likely to be adversely impacted. The effects of recession can also increase economic instability with vendors and customers. F-34 NEWGENIVF LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021
(Stated in US Dollars) NOTE 18 — CONTINGENCIES As of December 31, 2023 and 202